NCT00551915View on ClinicalTrials.gov

A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

PHASE2CompletedINTERVENTIONAL

Enrollment

756

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions

Bacterial Infections; Virus Diseases

Interventions

BIOLOGICAL

AR51 (12, 10)

vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg

BIOLOGICAL

PR51 (3, 10)

vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg

BIOLOGICAL

PR51 (6, 10)

vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg

BIOLOGICAL

PENTACEL™

licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label

BIOLOGICAL

RECOMBIVAX HB™

licensed vaccine for hepatitis, administered open-label

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00551915 - A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) | Biotech Hunter | Biotech Hunter